; (ii) illicit drug use in the workplace and the productivity lost by such use; and (iii) illicit drug use by arrestees, probationers, and parolees. (B) An assessment of the reduction of illicit drug availability, for each drug identified under section 1005(c)(1)(A)(i), as measured by— (i) the quantities of such drug available for consumption in the United States; (ii) the amount of such drug entering the United States; (iii) the number of illicit drug manufacturing laboratories seized and destroyed of each relevant drug and the number of hectares cultivated and destroyed domestically and in other countries of each relevant drug; (iv) the number of metric tons of such drug seized; and (v) changes in the price and purity of such drug. (C) An assessment of the reduction of the consequences of illicit drug use and availability, which shall include— (i) the cost of treating substance use disorder in the United States, such as the quantity of illicit drug-related services provided; (ii) the annual national health care cost of illicit drug use; and (iii) the extent of illicit drug-related crime and criminal activity. (D) A determination of the status of drug treatment in the United States, by assessing— (i) public and private treatment utilization; and (ii) the number of illicit drug users the Director estimates meet diagnostic criteria for treatment. (E) A summary of the efforts made to coordinate with private sector entities to conduct private research and development of medications to treat addiction by— (i) screening chemicals for potential therapeutic value; (ii) developing promising compounds; (iii) conducting clinical trials; (iv) seeking Food and Drug Administration approval for drugs to treat addiction; (v) marketing the drug for the treatment of addiction; (vi) urging physicians to use the drug in the treatment of addiction